AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer

Shots:

• The P-III PAOLA-1 study involves assessing of Lynparza + bevacizumab vs bevacizumab as monothx. as a 1L maintenance therapy for newly diagnosed advanced FIGO Stage III-IV high grade serous or endometroid ovarian, fallopian tube, peritoneal cancer women prior treated with platinum-based CT + bevacizumab
• The P-III PAOLA-1 study resulted in meeting its 1EPs in the intent-to-treat population i.e, improvement in PFS, increased the time women lived without disease progression, no new safety is observed
• Lynparza is a PARP inhibitor act by blocking DNA damage response in tumors harboring HRR mutation including BRCA1/BRCA2, jointly developed and commercialized by AstraZeneca and MSD and is an approved therapy for the treatment of advanced ovarian cancer and metastatic breast cancer

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Livemint